Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model.
Ritter
C A
CA
Department of Hematology-Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA. ritter@uni-greifswald.de
Bianco
R
R
Dugger
T
T
Forbes
J
J
Qu
S
S
Rinehart
C
C
King
W
W
Arteaga
C L
CL
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D000069347:Erlotinib Hydrochloride; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000069347:Erlotinib Hydrochloride; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab